Supreme Court Rules in Favor of Teva Over Patent for Multiple Sclerosis Drug

The Supreme Court on Tuesday ruled that Teva Pharmaceutical Industries could still benefit from patent protection for a multiple sclerosis drug, dealing a blow to makers of generic drugs.

In a 7-2 vote, the justices sent the case back to the United States Court of Appeals for the Federal Circuit for further review, saying it had not used the correct approach in analyzing whether the patent, due to expire in September, was valid. The appeals court had thrown out the patent in 2013.